WST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
West Pharmaceutical Services Inc (WST) shows strong financial performance and raised guidance, which are positive indicators for long-term investors. However, the stock is currently overbought (RSI of 90.368), and analysts have mixed views with some lowering price targets. Additionally, the stock's short-term trend suggests potential downside in the next week and month. Given the investor's beginner level and long-term focus, it is advisable to hold off on buying at this elevated level and wait for a better entry point.
The stock is in a bullish trend with MACD positively expanding and moving averages showing strength (SMA_5 > SMA_20 > SMA_200). However, the RSI of 90.368 indicates the stock is overbought, suggesting a potential pullback. Key resistance levels are at R1: 307.798 and R2: 323.32.
Strong Q1 2026 financial performance with revenue up 21.05% YoY and EPS up 56.10% YoY.
Raised full-year guidance and Q2 2026 outlook.
Hedge funds are increasing their positions significantly, with a 196.32% increase in buying over the last quarter.
Overbought technical condition (RSI of 90.368).
Analysts have mixed ratings, with several lowering price targets due to concerns about GLP-1 revenue risks.
Short-term stock trend indicates potential downside (-1.14% in the next week, -8.96% in the next month).
West Pharmaceutical Services reported Q1 2026 revenue of $844.9 million, up 21.05% YoY. Net income increased by 54.57% YoY to $138.8 million, and EPS rose 56.10% YoY to $1.92. Gross margin improved to 35.08%, up 5.60% YoY.
Analysts have mixed views. Barclays raised its price target to $275 but maintains an Equal Weight rating, citing risks in the life sciences sector. Deutsche Bank and UBS maintain Buy ratings with targets of $315 and $340, respectively. However, several analysts, including BofA and Jefferies, have lowered price targets due to concerns about GLP-1 revenue risks and group compression.
